CJC-1295 + Ipamorelin 10 mg total — Lyophilized Vial 10 mg total · 1 vial

What is CJC-1295 + Ipamorelin?

This research blend combines CJC-1295 and ipamorelin in one research blend. The components are associated with two different routes of stimulating growth-hormone secretion: the GHRH pathway and the growth-hormone-secretagogue pathway.

Biological activity

CJC-related GHRH analogs and ipamorelin act through different receptor systems. Their pairing provides a way to investigate interactions within the GH/IGF-1 axis. The exact CJC form matters: findings for albumin-binding CJC-1295 with DAC must not be transferred to a no-DAC blend without qualification.

Purpose and areas of study

The research purpose is to study hormone-release patterns and the response to combined secretagogue pathways. It is a mechanistic research concept, not established proof that the blend improves sleep, muscle growth, fat loss or recovery.

Evidence context

Individual-compound findings do not demonstrate clinical effects of this blend. Confirm the CJC form and component quantities; the labeled 10 mg is the combined content.

Product presentation

One lyophilized vial. Labeled content: 10 mg total.

Scientific references

PubMed 16352683; PubMed 9849822

Research-use information

All information on this page is provided for scientific education and research purposes only. This product is intended exclusively for laboratory research and is not for human or veterinary use. The information is not medical advice or a claim of therapeutic benefit.